PepGen Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON, MA, 02210
Mailing Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON, MA, 02210
Phone
703-456-8000
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$32.26M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 8-K Current report of material events | March 4, 2026 | View on SEC |
| 8-K Current report of material events | March 4, 2026 | View on SEC |
| 10-K Annual financial report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
Annual Reports
10-K
March 4, 2026
- Advanced PGN-101 into Phase 1 clinical trial in Q3 2025, with initial safety data expected mid-2026.
- Continued preclinical development for PGN-202 (Oncology) with IND-enabling studies planned for Q4 2026.
Material Events
8-K
Other
March 4, 2026
High Impact
- PGN-EDODM1 achieved the "highest ever reported mean splicing correction" in DM1 patients after a single dose.
- The drug demonstrated up to 53.7% splicing correction at the highest dose (15 mg/kg), indicating potential as a "best-in-class" treatment.
Insider Trading
SELL
3 insiders
6 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.